|
(MoneyNewsWire.Net, September 08, 2017 ) The Europe Plasma Fractionation Market was worth USD 5.24 billion in 2016 and is projected to be growing at a CAGR of 6.10%, to touch USD 7.04 billion by 2021.
Get Report Brochure @ http://www.orbisresearch.com/contacts/request-sample/391482
Plasma Fractionation consists of screening ad fractionating procedure in which the blood is split into its constituents of the plasma and RBCs, WBCs and platelets. The plasma is studied for various deficiencies and replaced, or treatment is prescribed.
Plasma is a necessary constituent of blood as it constitutes about 55% blood by volume and carries more than a thousand proteins and other substances like electrolytes, hormones which are required for the optimal function of the human body. Albumin is one of the major proteins which is replaced and also used to compensate during plasma exchange.
The growth of the Europe Plasma Fractionation Market is mainly driven by factors such as the increasing incidence of immune and bleeding disorders, growing incidence of Alpha-1 Antitrypsin deficiency and the rising use of immunoglobulins. Further, increasing aging population with related blood related ailments is set to promote market growth. However, adverse reactions associated with the use of plasma fractionation and transfer, high costs of plasma products and unfavourable reimbursement policies are the major constraints of market growth.
Market Segmentation:
The Europe Plasma Fractionation Market is segment on the basis of Product, Application, End User and Geography. Based on Product, the market is divided into Albumin, Immunoglobulin, Factor VIII, and Protease Inhibitors. Based on Application, the Plasma Fractionation Market is segmented into Neurology, Haematology, Rheumatology, Pulmonology, and Immunology. Based on the End User, it is categorized into Hospital and Clinical Laboratories.
The Europe market has been geographically segmented into Germany, U.K, France, Spain, and Italy. Europe holds the second position in terms of market share globally. There is potential for market growth due to the presence of some untapped markets coupled with the rising frequency of blood related disorders. Rising elderly population with consequent blood disorders is also a contributor to market growth in this region.
Key Players in this market :
The important players in the Europe Plasma Fractionation market are CSL Ltd. (Australia), Grifols S.A (Spain), Baxalta Incorporated (U.S.), Octapharma AG (Switzerland), Kedrion S.p.A (Italy), Bio Products Laboratory (U.K.), Sanquin (Netherland), China Biologic Products, Inc. (China), Biotest AG (Germany), and Laboratoire Français du Fractionnement et des Biotechnologies (France).
Browse Full Report @ http://www.orbisresearch.com/reports/index/europe-plasma-fractionation-market-by-product-application-end-user-and-by-region-industry-analysis-size-share-growth-trends-and-forecasts-2016-2021
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Orbis Research
Hector Costello
+1 (214) 884-6817
sales@orbisresearch.com
Source: EmailWire.Com 
|
